Shroff
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses
Every single patient with advanced pancreatic cancer who walked into Dr. Zev Wainberg’s office told him they would rather take an experimental medication than endure another round of chemotherapy. Wainberg, co-director of UCLA Health’s GI Oncology Program, was leading a clinical trial of a new drug called daraxonrasib. All the study participants previously had chemotherapy that was starting to fail.
Daily pill can double survival time for deadliest cancer, trial shows
A daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a “gamechanger” and one of the biggest breakthroughs in decades. Currently, there are few treatments for pancreatic cancer, and most do little or nothing to help. For decades, scientists have worked relentlessly trying to find clever solutions for a form of cancer that is often found late.
Cancer breakthrough as new 'game-changing' pill could DOUBLE survival time for most deadly diseases
Cancer breakthrough as new 'game-changing' pill could DOUBLE survival time for most deadly diseases Prostate cancer patients normally have a devastatingly short life expectancy - but the new daily pill being offered in clinical trials could change that A “game-changing” daily pill helped almost double survival time for patients with the most deadly major cancer. Pancreatic cancer patients on the drug lived for twice as long as those on chemotherapy. The pill’s success is thought to be the...
Pancreatic cancer: New drug results prompt standing ovation at oncology conference
A new drug for advanced pancreatic cancer is being hailed as a major breakthrough after trial results showed that it almost doubles survival time in patients previously treated with chemotherapy. Phase 3 trial results for daraxonrasib, a once daily oral treatment, have been described as a potential “revolution” in treating pancreatic cancer, which has the lowest survival of all common cancers, with five year survival less than 7%.In the RASolute 302 trial of 500 patients with metastatic...